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Myosin Binding Protein-C Slow 
Phosphorylation is Altered 
in Duchenne Dystrophy and 
Arthrogryposis Myopathy in Fast-
Twitch Skeletal Muscles
Maegen A. Ackermann1, Christopher W. Ward2, Christina Gurnett3 & 
Aikaterini Kontrogianni-Konstantopoulos1
Myosin Binding Protein-C slow (sMyBP-C), encoded by MYBPC1, comprises a family of regulatory 
proteins of skeletal muscles that are phosphorylated by PKA and PKC. MYBPC1 missense mutations 
are linked to the development of Distal Arthrogryposis-1 (DA-1). Although structure-function details 
for this myopathy are evolving, function is undoubtedly driven by sequence variations and post-
translational modifications in sMyBP-C. Herein, we examined the phosphorylation profile of sMyBP-C 
in mouse and human fast-twitch skeletal muscles. We used Flexor Digitorum Brevis (FDB) isolated 
from young (~2-months old) and old (~14-months old) wild type and mdx mice, and human Abductor 
Hallucis (AH) and gastrocnemious muscles carrying the DA-1 mutations. Our results indicate both 
constitutive and differential phosphorylation of sMyBP-C in aged and diseased muscles. We report a 
7–35% reduction in the phosphorylation levels of select sites in old wild type and young or old mdx 
FDB mouse muscles, compared to young wild type tissue. Similarly, we observe a 30–70% decrease in 
the phosphorylation levels of all PKA and PKC phospho-sites in the DA-1 AH, but not gastrocnemius, 
muscle. Overall, our studies show that the phosphorylation pattern of sMyBP-C is differentially 
regulated in response to age and disease, suggesting that phosphorylation plays important roles in 
these processes.
Myosin Binding Protein-C (MyBP-C) is a family of accessory proteins of striated muscles that contrib-
utes to thick filament assembly and stabilization, and modulates contraction by regulating the forma-
tion of actomyosin cross-bridges1–8. The slow (s) skeletal isoform of MyBP-C, which is encoded by the 
MYBPC1 gene, is comprised of seven immunoglobulin (Ig) and three fibronectin-III (Fn-III) domains. 
The first Ig domain, C1, is flanked by a short stretch of amino acids (~50 aa) enriched in proline (Pro) 
and alanine (Ala) residues, termed Pro/Ala rich motif, and a conserved linker region (~100 aa), noted 
the M-motif. Differing from the cardiac and fast skeletal homologues, sMyBP-C consists of a hetero-
geneous family of proteins (126–131.5 kDa) that result from extensive exon shuffling9,10. The human 
transcriptome contains fourteen sMyBP-C transcripts, which encode fourteen distinct variants, differing 
by small segments of amino acids within the Pro/Ala rich motif, the M-motif, the Ig domain C7, and 
the extreme COOH-terminus10. To date, five full-length sMyBP-C variants have been identified in the 
mouse transcriptome, however it is likely that the known human variants correspond to unidentified 
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mouse variants. Interestingly, the sMyBP-C variants are co-expressed in both slow and fast twitch skeletal 
muscles where they may exhibit distinct topographies and functions1,2,9.
MyBP-C slow is phosphorylated at four residues within the Pro/Ala rich region and the M-motif at 
its NH2-terminus11. These four sites (mSer-59/hSer-61, mSer-62/hThr-64, mThr-84/hSer-85, and mSer-
204/hSer-206) are conserved between mouse (m) and human (h) sMyBP-C and are phosphorylated by 
PKA and/or PKC11. Specifically, mSer-59/hSer-61 and mSer-62/hThr-64 are targeted by PKA, mThr-84/
hSer-85 is phosphorylated by PKC, and mSer-204/hSer-206 is a substrate of both PKA and PKC. Of the 
four phosphorylation sites, mSer-62/hThr-64 and mThr-84/hSer-85 are constitutively expressed in all 
known mouse and human variants (Fig. 1, grey highlighted residues). Contrary to this, mSer-59/hSer-61 
and mSer-204/hSer-206 are encoded by exons that are alternatively spliced, and are thus present only in 
select variants (Fig. 1, purple and green highlighted residues, respectively). Accordingly, mSer-59/hSer-
61, present within the Pro/Ala rich motif, is expressed only in h-variant (v) 1, h-v2, and m-isoform3, 
while mSer-204/hSer-206, present within the M-motif, is expressed in all variants with the exception 
of h-v8. Therefore, alternative splicing and phosphorylation may regulate the activities of the different 
sMyBP-C variants.
Genomic linkage analysis has demonstrated that mutations in MYBPC1 are causally linked to the 
development of distal arthrogryposis type-1 (DA-1)12. DA-1 is the most common among the ~10 forms 
of distal arthrogryposis myopathy that have been described to date affecting approximately 1 in 10,000 
individuals13,14. Two dominant missense mutations, W236R and Y856H, have been identified, which are 
located in the M-motif and C8 domain, respectively. Although the DA-1 causing mutations are present 
in constitutively expressed exons and thus contained in all slow variants expressed in skeletal muscles, 
DA-1 patients have contractures that are limited to the distal muscles of the hands and feet, includ-
ing clubfoot, vertical talus, camptodactyly, overriding fingers and ulnar deviation of fingers with no 
additional anomalies12. The congenital nature of the DA-1 contractures has been attributed to the early 
embryonic expression of sMyBP-C, which precedes that of MYBPC2 encoding the fast skeletal isoform15. 
Importantly, the presence of the DA-1 mutations abolishes the proteins’ ability to interact with actin and 
Figure 1. The NH2-terminus of sMyBP-C is subjected to phosphorylation. Schematic representation 
of the NH2-terminus of the known human and mouse sMyBP-C variants with the phosphorylation sites 
highlighted. The Pro/Ala rich and M- motifs are denoted as dark and light grey rectangles, respectively, and 
the first Ig domain (C1) is shown as a white oval. Colored rectangles indicate short stretches of amino acids 
that are products of alternatively spliced regions.
www.nature.com/scientificreports/
3Scientific RepoRts | 5:13235 | DOi: 10.1038/srep13235
myosin and regulate the formation of cross-bridges in vitro2. However, the effects of either of the DA-1 
mutations on the phosphorylation profile of sMyBP-C are still unknown. Along the same lines, earlier 
studies have demonstrated that loss of dystrophin in Duchenne Muscular Dystrophy (DMD) leads to 
a number of adaptive and maladaptive responses, including alterations in global protein phosphoryla-
tion16,17. As in DA-1 though, the phosphorylation profile of sMyBP-C has yet to be described in DMD.
Using a panel of phospho-specific antibodies in conjunction with standard and phosphate affinity 
SDS-PAGE, we examined the phosphorylation profile of sMyBP-C in different mouse and human skeletal 
muscles. Specifically, we compared the phosphorylation profile of sMyBP-C in young (~2 months old) 
and old (~14 months old) fast-twitch Flexor Digitorum Brevis (FDB) muscles obtained from wild type 
and mdx mice, and human Abductor Hallucis (AH) and gastrocnemius fast-twitch muscles carrying 
the Y856H and W236R mutations, respectively. Our studies demonstrate that while overall phospho-
rylation is only moderately decreased at select sites in young and old wild type and mdx muscles, there 
are qualitative and quantitative differences in individual phosphorylation events as a result of age and/
or dystrophy. Moreover, the phosphorylation profile of sMyBP-C is significantly altered in human AH 
muscle, which is severely affected in DA-1, but not in gastrocnemius muscle, which shows no phenotypic 
manifestation of the disease. Collectively, our studies are the first to demonstrate that the phosphoryla-
tion pattern of sMyBP-C is differentially regulated in response to age and disease.
Results
Characterization of the phosphorylation profile of sMyBP-C in the mouse fast-twitch FDB 
muscle in health and dystrophy. Our recent studies have demonstrated that sMyBP-C encompasses 
a family of phosphoproteins with mSer-59 and mSer-62 phosphorylated by PKA, mThr-84 phospho-
rylated by PKC, and mSer-204 phosphorylated by both PKA and PKC11. To study the phosphorylation 
profile of sMyBP-C in fast-twitch skeletal muscles in response to different (patho)physiological stressors, 
such as aging and disease, we selected the mouse FDB muscle because of the abundant expression of 
several sMyBP-C variants9,10. We produced lysates from young (~2 months) and old (~14 months) wild 
type and mdx FDB muscles, which were analyzed by conventional and phosphate-affinity gel electropho-
resis and subsequent immunoblotting. Moreover, we used a panel of antibodies including a sMyBP-C 
antibody that recognizes constitutively expressed epitopes in the C5 domain (α -pan-sMyBP-C), and 
four phospho-specific antibodies recognizing all known phosphorylation sites (α -sMyBP-C mSer59P, 
α -sMyBP-C mSer62P, α -sMyBP-C mThr84P, and α -sMyBP-C mSer204P). It is important to note that 
due to the presence of multiple sMyBP-C variants with similar molecular weights (126–131.5 kDa)10, the 
immunoreactive bands detected in our phosphate-affinity blots may correspond to unique variants phos-
phorylated to differing extents, differentially phosphorylated forms of the same variant, or a combination 
of both. Consequently, we refrain from denoting those as hyper- or hypo-phosphorylated species and 
instead refer to them according to their electrophoretic mobility as low, intermediate, or high. Moreover, 
we consider young wild type FDB tissue as reference, and report qualitative and quantitative differences 
in the other conditions that deviate from it.
Using standard SDS-PAGE immunoblotting, we examined the expression levels of sMyBP-C in the 
different FDB muscles described above. We observed a consistent and significant reduction (~25%) in 
the total levels of sMyBP-C in aged wild type and young or aged mdx FDB muscles, compared to young 
wild type tissue (Fig. 2a,a’). Analysis of the phosphorylation profile of sMyBP-C in young wild type FDB 
muscle using the α -pan-sMyBP-C antibody and phosphate-affinity SDS-PAGE indicated the presence 
of seven distinct forms of different electrophoretic mobility (Fig.  2b). For ease of presentation, we use 
colored dots to denote the observed immunoreactive bands. We detected one low mobility band (yellow 
dot), five intermediate mobility bands (dark green, turquoise, dark blue, purple, and brown dots), and 
one high mobility band (pink dot). Aged wild type FDB muscle expresses six of the seven sMyBP-C spe-
cies present in the young wild type tissue, in addition to two new forms of low (red dot) and intermediate 
(bright yellow dot) mobility, thus containing a total of eight sMyBP-C phospho-species (Fig. 2b). Young 
and aged mdx FDB muscles also express the same seven major forms as young wild type FDB muscle, 
in addition to an intermediate mobility species (bright yellow dot) that is also present in aged wild type 
FDB muscle (Fig. 2b).
Evaluation of the phosphorylation levels of mSer59, mSer62, mThr84, and mSer204 of 
sMyBP-C in mouse FDB muscle in health and dystrophy. Using standard SDS-PAGE along with 
our panel of phospho-specific antibodies (Ackermann et al. 2014; Companion paper), we examined the 
phosphorylation levels of each known phospho-site within the NH2-terminus of sMyBP-C in young and 
aged wild type and mdx FDB muscles. As above, the young wild type FDB muscle was used as the basis 
for qualitative and quantitative comparisons.
Analysis of lysates probed with the mSer59P, mSer62P, mThr84P, or mSer204P antibodies indicated 
that young and aged, wild type and mdx FDB muscles contain sMyBP-C variants that are phosphoryl-
ated at each of the corresponding sites (Fig.  3a–d). Use of the mSer59P antibody demonstrated that 
the expression levels of phospho (p) mSer59-containing variants remain unaltered in aged wild type 
FDB muscle, compared to young wild type tissue; however, they decrease dramatically in young mdx 
(~34%) and moderately in old mdx (~11%) FDB muscles (Fig. 3a’). Similar quantitation of the amounts 
of p-mSer62-containing proteins showed that while aged wild type FDB contains similar levels to young 
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wild type tissue, young and old mdx FDB express reduced levels (~12% and ~8%, respectively) (Fig. 3b’). 
Contrary to this, evaluation of the expression levels of p-mThr84-containing variants revealed that com-
pared to young wild type tissue, young and aged mdx FDB contain similar levels, while old wild type FDB 
exhibits reduced amounts by ~21% (Fig. 3c’). Lastly, quantitation of the levels of p-mSer204-containing 
proteins showed that they remain unaltered in old wild type and young or old mdx FDB, compared to 
young wild type tissue (Fig. 3d’).
Identification of the phosphorylation events present in individual sMyBP-C forms in young 
and aged healthy and diseased FDB muscles. To identify the phosphorylation events present 
within the individual sMyBP-C phospho-species detected with our α -pan-sMyBP-C antibody (Fig. 2b), 
we used phosphate affinity SDS-PAGE and our panel of phospho-specific antibodies (Figs 4 and 5).
Protein lysates prepared from young wild type FDB muscle probed with the mSer59P antibody con-
tain two main species, one of low mobility (yellow dot) and one of high mobility (pink dot) (Fig. 4a). 
These are the only two phospho-species present in aged wild type and mdx FDB muscles, too, while 
young mdx FDB also expresses an intermediate mobility band (dark blue dot) (Fig. 4a).
Use of the mSer62P antibody revealed the presence of common and unique phospho-species com-
pared to the mSer59P antibody. Two intermediate mobility species (purple and brown dots) were detected 
in young wild type FDB muscle (Fig. 4b). These are also present in aged wild type and young and aged 
mdx FDB muscles, albeit in differing amounts (Fig.  4b). Aged wild type FDB also expresses two low 
mobility p-mSer62-containing forms (red and yellow dots). Of those, the low mobility band denoted by 
the yellow dot is present in young mdx FDB samples, too (Fig. 4b).
Similar analysis using the mThr84P antibody indicated the presence of four major species in young 
wild type and mdx FDB muscles (Fig. 4c, yellow, dark blue, brown, and pink dots). Notably, p-mSer59 
and/or p-mSer62 antibodies detect these species, too (Fig. 4c). Examination of aged wild type and mdx 
tissues indicated a similar expression profile of p-mThr84-containing species, compared to young wild 
type and mdx FDB muscles, with the following exceptions: aged wild type tissue lacks a high (pink dot) 
and an intermediate (dark blue dot) mobility species, while aged mdx tissue only lacks the high mobility 
species (pink dot) (Fig. 4c).
Lastly, evaluation of the expression profile of p-mSer204-containing proteins indicated the presence 
of four main species in young wild type FDB muscle, one of low mobility (yellow dot) and three of 
intermediate mobility (dark green, turquoise, and purple dots) (Fig. 4d). While the low (yellow dot) and 
intermediate (purple dot) mobility species are detected by other phospho-antibodies, the remaining two 
species (dark green and turquoise dots) are unique to mSer204P antibody. Similar to young wild type, 
aged wild type and young and aged mdx FDB muscles express the same four p-mSer204-containing 
forms (Fig. 4d), with the aged wild type and young mdx tissues containing an additional form of inter-
mediate mobility (bright yellow dot) (Fig. 4d).
Figure 2. Evaluation of the phosphorylation profile of sMyBP-C in young and old wild type and mdx 
FDB muscles. (a) Standard SDS-PAGE western blot analysis of protein lysates prepared from young (~2 
months) and old (~14 months) wild type and mdx FDB muscles. Lysates were probed with a α -pan-
sMyBP-C (top panel) recognizing all sMyBP-C variants, and α -Hsp90 (bottom panel) to ensure equal 
loading. (a’) Percent expression of total sMyBP-C in young and old wild type and mdx FDB muscles, after 
normalization to the levels of Hsp90, and relative to the percent expression of sMyBP-C in young wild 
type tissue, which was set as baseline. Significance was calculated via student’s t-test (p < 0.01). The star (*) 
symbol denotes significance compared to young wild type. (b) Separation of the same protein lysates used in 
panel (a) via phosphate affinity SDS-PAGE followed by immunoprobing with the α -pan-sMyBP-C antibody. 
Colored dots represent immunoreactive bands of low (red and yellow dots), intermediate (bright yellow, 
dark green, turquoise, dark blue, purple, and brown dots), and high (pink dot) mobility. Four animals 
(n = 4) were used per group.
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Examination of the phosphorylation profile of sMyBP-C in human abductor hallucis and gas-
trocnemius muscles from DA-1 patients. Two missense mutations, W236R and Y856H, in human 
MYBPC1 have been causally linked to the development of distal arthrogryposis type-1 (DA-1), affecting 
Figure 3. Examination of the phosphorylation levels of mSer59, mSer62, mThr84, and mSer204 of 
sMyBP-C in fast-twitch FDB muscles of young and old wild type and mdx mice. Western blot analyses 
were performed using standard SDS-PAGE and lysates prepared from young (~2 months) and old (~14 
months) wild type and mdx FDB muscles. Samples were probed with α -sMyBP-C mSer59P (a), α -sMyBP-C 
mSer62P (b), α -sMyBP-C mThr84P (c), and α -sMyBP-C mSer204P (d) recognizing the four known 
phospho-sites of sMyBP-C. The levels of each phosphorylated residue, mSer59 (a’), mSer62 (b’), mThr84 
(c’), and mSer204 (d’) in the different FDB muscles were calculated as percent expression relative to those 
in young wild type tissue, as described in Fig. 2. Four animals (n = 4) were used per group. Significance was 
calculated via student’s t-test (p < 0.01). The symbols, *, #, and @ denote significance compared to young 
wild type, young mdx, and old wild type, respectively.
www.nature.com/scientificreports/
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the distal muscles of the hands and feet12. W236R and Y856H are located within the M-motif and C8 
domain, respectively. Both mutations reside in constitutively expressed exons, and are therefore present 
within all known sMyBP-C variants. To study the effects of each of these mutations on the phospho-
rylation profile of sMyBP-C, we used human biopsies of the abductor hallucis (AH) and gastrocnemius 
muscles carrying the Y856H and W236R mutations, respectively; AH and gastrocnemius muscles that 
did not contain the DA-1 mutations served as controls. We generated protein lysates from the DA-1 
and control muscles and analyzed them by conventional or phosphate affinity gel electrophoresis and 
subsequent immunoblotting with the α -pan-sMyBP-C and the four phospho-specific antibodies. As a 
result of the high homology of the four phospho-sites between mouse and human (Fig. 6a), our panel 
of phospho-antibodies efficiently recognizes the human sMyBP-C proteins, too. Similar to our results 
with FDB (above) and soleus (Ackermann et al., 2014; Companion paper), the immunoreactive bands 
detected in the phosphate affinity blots may correspond to different variants phosphorylated to variable 
extents, differentially phosphorylated forms of the same variant, or a combination of both. We therefore 
also refer to the immunoreactive bands detected in the human DA-1 and control muscles as low, inter-
mediate, or high mobility, and we further correlate them with the respective bands detected in mouse 
FDB (this study) and soleus (Ackermann et al., 2014; Companion paper) muscles, when applicable.
Using standard SDS-PAGE immunoblotting, we observed a significant reduction (~25%) of total 
sMyBP-C in DA-1 AH muscle carrying the Y856H mutation, compared to control tissue (Fig. 6b,b’). On 
the contrary, the sMyBP-C levels are unaltered in DA-1 gastrocnemius muscle containing the W236R 
mutation, compared to control muscle (Fig.  6b,b’). Examination of the phosphorylation profile of 
sMyBP-C in control AH muscle using the α -pan-sMyBP-C antibody and phosphate-affinity SDS-PAGE 
revealed six different species, three of low mobility (red, yellow, and blue dots) and three of intermediate 
mobility (light yellow, olive green, and dark blue dots) (Fig. 6c). DA-1 AH muscle expresses five of these 
species and two additional species of intermediate (turquoise dot) and high (purple dot) mobility. Similar 
examination of the phosphorylation profile of sMyBP-C in control gastrocnemius muscle showed eight 
different species, three of low (red, yellow, and blue dots), four of intermediate (light yellow, olive green, 
light green, and dark blue dots) and one of high (light purple dot) mobility. Contrary to DA-1 AH mus-
cle, the phosphorylation profile of sMyBP-C is not altered in DA-1 gastrocnemius muscle carrying the 
W236R mutation, compared to control muscle.
Evaluation of the phosphorylation levels of hSer61, hThr64, hSer85, and hSer206 of sMyBP-C 
in human abductor hallucis and gastrocnemius muscles from DA-1 patients. Using standard 
SDS-PAGE along with our panel of phospho-specific antibodies, we examined the phosphorylation levels 
of each phospho-site within the NH2-terminus of sMyBP-C in AH and gastrocnemius muscles carrying 
the Y856H and W236R mutations, respectively. As above, AH and gastrocnemius muscles served as 
controls, and were used as the basis for qualitative and quantitative comparisons.
Analysis of lysates probed with the mSer59P, mSer62P, mThr84P, and mSer204P antibodies indicated 
that control and DA-1 AH and gastrocnemius muscles express sMyBP-C variants that are phosphoryl-
ated at each of the four known sites (Fig. 7a–d). Interestingly though, the expression levels of variants 
phosphorylated at hSer61, hThr64, hSer85 or hSer206 are dramatically decreased by ~70%, ~65%, ~37% 
and ~32%, respectively, in DA-1 AH muscle carrying the Y856H mutation, compared to control tissue 
(Fig. 7a’–d’). On the contrary, DA-1 gastrocnemius muscle carrying the W236R mutation shows no sig-
nificant changes in the phosphorylation levels of the four sites, compared to control (Fig. 7a’–d’).
Figure 4. Identification of distinct phosphorylation events present in individual sMyBP-C forms in fast-
twitch FDB muscles of young and old wild type and mdx mice. Western blot analysis using phosphate 
affinity SDS-PAGE blots of protein lysates obtained from young (~2 months) and old (~14 months) 
wild type and mdx FDB muscles were probed with α -sMyBP-C mSer59P (a), α -sMyBP-C mSer62P (b), 
α -sMyBP-C mThr84P (c), and α -sMyBP-C mSer204P (d). Colored dots denote low, intermediate, and high 
mobility sMyBP-C species identified with each antibody, and correspond to those shown in Fig. 2. Four 
animals (n = 4) were used per group.
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Examination of the phosphorylation events present in individual sMyBP-C forms in human 
abductor hallucis and gastrocnemius muscles from DA-1 patients. We next examined the phos-
phorylation events present within the individual sMyBP-C species detected with our α -pan-sMyBP-C 
antibody (Fig.  6b) using phosphate-affinity SDS-PAGE and our panel of phospho-specific antibodies 
(Fig. 8). Control AH muscle expresses four main p-hSer61-containing species, three of low (red, yellow, 
and blue dots) and one of intermediate (dark blue dot) mobility (Fig.  8a). DA-1 AH muscle expresses 
the same low (blue dot) and intermediate (dark blue dot) mobility forms and an additional species of 
intermediate mobility (turquoise dot) (Fig.  8a). Contrary to this, similar analysis of control and DA-1 
gastrocnemius muscles indicated that they express the same four main species, two of low mobility (red 
and blue dots) and two of intermediate mobility (light green and dark blue dots).
Three distinct p-hThr64-containing species of low (blue dot) and intermediate (light yellow and olive 
green dots) mobility were observed in control AH muscle (Fig. 8b). Two of them, including the low (blue 
dot) and intermediate (light yellow dot) mobility species are also present in DA-1 AH muscle, which 
also expresses an additional low mobility species (yellow dot) (Fig. 8b). Similar to the mSer59P antibody, 
the mSer62P antibody revealed a matching phosphorylation profile of sMyBP-C in control and DA-1 
gastrocnemius samples, which express a low (blue dot) and three intermediate (light yellow, olive green, 
and light green dots) mobility species (Fig. 8b).
Figure 5. Relative abundance and phosphorylation profile of distinct sMyBP-C forms in fast-twitch FDB 
muscles of young and old wild type and mdx mice. (a) The relative abundance of each immunoreactive 
band detected with the α -pan-sMyBP-C antibody following separation of protein lysates by phosphate 
affinity SDS-PAGE (Fig. 2b) was calculated as percent expression of the total protein content within 
each sample. Significance is as described in Fig. 2a’. (b) The phosphorylation events detected in each 
sMyBP-C form across the different FDB muscle groups were identified by comparative evaluation of the 
phosphate affinity SDS-PAGE immunoblots shown in Fig. 4. Notably, colored dots correspond to sMyBP-C 
immunoreactive bands with specific electrophoretic mobility, as determined by phosphate affinity SDS-
PAGE, and thus may represent different (i.e. bands denoted with purple and pink dots) or the same (bands 
denoted with red, yellow, bright yellow, dark green, turquoise, dark blue, and white dots) phospho-species 
among FDB samples.
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Moreover, control AH contains two major p-hSer85-containing species of low mobility (blue and light 
yellow dots), which are also present in DA-1 AH muscle in addition to an extra low mobility form (red 
dot) (Fig. 8c). As above, examination of control and DA-1 gastrocnemius muscles indicated an identical 
expression profile of p-hSer85-containing species, including three low mobility forms (red, blue, and 
light yellow dots) (Fig. 8c).
Lastly, evaluation of the expression profile of p-hSer206-containing proteins indicated the presence of 
two main species in control AH muscle, both of low mobility (red and yellow dots) (Fig. 8d). DA-1 AH 
tissue also expresses the low mobility species denoted by the yellow dot, along with additional low (blue 
dot) and intermediate (purple dot) mobility forms (Fig.  8d). Control gastrocnemius muscle contains 
three main species, of low (yellow dot), intermediate (dark blue dot), and high (light purple dot) mobility, 
all of which are shared with DA-1 gastrocnemius muscle (Fig. 8d).
Discussion
The phosphorylation profile of sMyBP-C in fast-twitch FDB muscle in health and dystro-
phy. To complement our assessment of the phosphorylation profile of the slow isoform of MyBP-C 
in slow-twitch soleus muscle (Ackermann et al. ’14; Companion paper), we herein determine its phos-
phorylation profile in fast-twitch FDB muscle under different (patho)physiological conditions. To this 
end, we used standard and phosphate-affinity gel electrophoresis in combination with a panel of phos-
pho-specific antibodies to examine the phosphorylation profile of sMyBP-C in healthy and dystrophic 
FDB muscles of mouse origin at early and late adulthood. Interestingly, both age and dystrophy result 
in a significant decrease (~25%) in the total levels of sMyBP-C (Fig. 5a). This finding is in contradiction 
to our previous report showing no apparent differences in total sMyBP-C protein between 4 months old 
wild type and mdx FDB11. Underlying this contradiction is likely the temporal progression of disease 
Figure 6. Examination of the phosphorylation profile of sMyBP-C in Abductor Hallucis (AH) and 
gastrocnemius muscles from human patients carrying the DA-1 mutations. (a) Alignment of sMyBP-C 
NH2-termini between mouse isoform 3 and human v1. Dark grey, white, and light grey boxes mark the 
Pro/Ala rich motif, domain C1, and the M-motif, respectively. The peptide sequences that were used for 
the generation of the four phospho-antibodies are marked with a line; notably, the sequence similarity and 
identity for each antigenic peptide between mouse and human are 100% and 90% for the Ser59 peptide, 82% 
and 45% for the Ser62 peptide, 100% and 85% for the Thr84 peptide, and 100% and 100% for the Ser204 
peptide, respectively. (b) Standard SDS-PAGE western blot analysis of protein lysates prepared from human 
biopsies of AH and gastrocnemius muscles carrying the Y856H and W236R DA-1 mutations, respectively, 
or control muscles; for details on the DA-1 and control muscles please see the Materials and Methods 
section. Lysates were probed with α -pan-sMyBP-C (top panel) and α -Hsp90 (bottom panel). (b’) Percent 
expression of total sMyBP-C in DA-1 AH and gastrocnemius muscles after normalization to the levels of 
Hsp90, and relative to the percent expression of sMyBP-C in matching controls. Significance was calculated 
via student’s t-test (p < 0.01). The star (*) symbol denotes significance compared to controls. (c) Separation 
via phosphate affinity SDS-PAGE of the same protein lysates used in panel (b) followed by probing with the 
α -pan-sMyBP-C antibody. Colored dots represent immunoreactive bands of low (red, yellow, and blue dots), 
intermediate (light yellow, olive green, light green, turquoise, dark blue, and purple dots), and high (light 
purple dot) mobility.
www.nature.com/scientificreports/
9Scientific RepoRts | 5:13235 | DOi: 10.1038/srep13235
Figure 7. Examination of the phosphorylation levels of hSer61, hThr64, hSer85, and hSer206 of 
sMyBP-C in AH and gastrocnemius muscles from human patients carrying the DA-1 mutations. Western 
blot analyses were performed using standard SDS-PAGE of lysates prepared from human biopsies of AH 
and gastrocnemius muscles carrying the Y856H and W236R DA-1 mutations, respectively, and matched 
control tissues. Samples were probed with α -sMyBP-C mSer59P (a), α -sMyBP-C mSer62P (b), α -sMyBP-C 
mThr84P (c), and α -sMyBP-C mSer204P (d) recognizing the four known phospho-sites of sMyBP-C in 
humans, too. The levels of each phosphorylated residue, hSer61 (a’), hThr64 (b’), hSer85 (c’), and hSer206 
(d’) in the DA-1 samples were calculated as percent expression relative to those in matching control tissues, 
as described in Fig. 6. Significance was calculated via student’s t-test (p < 0.01). The star (*) symbol denotes 
significance compared to controls.
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pathology. In the mdx mouse, the pathological process is evident from birth but dramatically accelerates 
post-weaning, peaking at ~6 weeks and resolving to a stable slow progression after ~20 weeks of age. The 
evolution of disease progression is reflected in muscle function18–21, and likely underscores the differen-
tial effect we observe on protein expression in 2 months old mice herein versus the 4 months old mice 
interrogated in our previous report11. Notably, we also observed a significant reduction in the overall 
phosphorylation of residues mSer59 and mSer62, both targeted by PKA. This is consistent with previous 
findings indicating that the enzymatic activity of PKA is significantly reduced (~24%) in dystrophic 
muscles22, which is likely due to mislocalization of A Kinase Anchoring Proteins (AKAP), which are 
scaffolding proteins that modulate the proper targeting of the regulatory subunit of PKA23. Moreover, 
the presence and relative abundance of individual phosphorylation events or combinations thereof vary 
considerably in response to age or dystrophy (Fig. 5a,b). Our studies therefore clearly demonstrate that 
the phosphorylation profile of sMyBP-C in fast-twitch FDB muscle is altered in response to different 
(patho)physiological stressors.
To comprehensively present our findings shown in Figs  2–4, we analyzed the relative abundance 
(Fig. 5a) and phosphorylation profile (Fig. 5b) of the individual sMyBP-C species expressed within and 
among the four FDB muscles examined. Of the seven unique sMyBP-C forms expressed in young wild 
type FDB muscle, a low mobility species (yellow dot) is the most abundant one (~35%) and is phos-
phorylated at all four known residues. Of similarly high abundance (~30%) is an intermediate mobility 
species (dark green dot), which is singly phosphorylated at mSer204, while a high mobility species (pink 
dot) also displays a relatively high expression (~20%), and is phosphorylated at mSer59 and mThr84. The 
remaining sMyBP-C forms are of substantially lower abundance (~3–5%), and are either doubly or singly 
phosphorylated. Notably, young wild type FDB and soleus muscles express many of the same mobility 
sMyBP-C species (yellow, dark green, turquoise, dark blue, and pink dots), albeit to different amounts 
and occasionally of distinct phosphorylation profiles (Ackermann et al., 2014; Companion paper, Fig. 6).
The molecular complexity of sMyBP-C may explain two paradoxical observations that we made in 
FDB muscle lysates analyzed by phosphate-affinity SDS-PAGE. sMyBP-C species containing one phos-
phorylation event (e.g. bands denoted with red and bright yellow dots) may migrate slower compared to 
species containing four phosphorylation events (e.g. band marked with a yellow dot). Moreover, sMyBP-C 
species exhibiting similar electrophoretic mobility among different FDB muscles may contain different 
numbers of phosphorylation events (e.g. bands denoted with purple and pink dots). Two possibilities 
may explain these findings: i. singly or doubly phosphorylated species may correspond to higher molec-
ular weight variants (126–131.5 kDa), or ii. lower molecular weight species may contain multiple (known 
and potentially unknown) phosphorylation events. Unlike the majority of the sMyBP-C species expressed 
in soleus muscle that are phosphorylated at multiple, if not all, known sites (Ackermann et al. 2014; 
Companion paper, Fig. 6), many of the forms expressed in FDB muscle are singly or doubly phospho-
rylated (Fig. 5b). Given that single phosphorylation events were detected at any of the four known sites, 
it becomes apparent that these can happen independently. Interestingly, three sMyBP-C species (bright 
yellow, dark green, and turquoise dots) are singly phosphorylated at mSer204, yet they exhibit distinct 
electrophoretic mobilities. We speculate that these correspond to different sMyBP-C variants of distinct 
molecular weights. Moreover, as in soleus muscle, we again note the absence of a non-phosphorylated 
species in FDB muscle. This may suggest that sMyBP-C is constitutively phosphorylated at basal levels. 
Figure 8. Identification of distinct phosphorylation events present in individual sMyBP-C forms 
in AH and gastrocnemius muscles from human patients carrying the DA-1 mutations. Western blot 
analysis using phosphate affinity SDS-PAGE blots of protein lysates obtained from human biopsies of AH 
and gastrocnemius muscles carrying the Y856H and W236R DA-1 mutations, respectively, and control 
muscles were probed with α -sMyBP-C mSer59P (a), α -sMyBP-C mSer62P (b), α -sMyBP-C mThr84P (c), 
and α -sMyBP-C mSer204P (d). Colored dots denote low, intermediate, and high mobility sMyBP-C species 
identified with each antibody, and correspond to those shown in Fig. 6.
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Conversely, it may be the result of coincident migration of non-phosphorylated higher molecular weight 
and singly or doubly phosphorylated lower molecular weight variants.
Compared to young wild type FDB muscle, the expression and relative abundance of select species 
varies significantly in aged or dystrophic FDB muscles (Fig.  5a). Accordingly, the low mobility species 
denoted with a red dot is only expressed in aged wild type FDB muscle where it exhibits a relatively 
low abundance (~10%). Notably, the intermediate mobility species marked with a bright yellow dot is 
expressed in aged wild type and young, but not old, mdx FDB muscles where it displays a relatively low 
expression (~5% and ~6%, respectively). Moreover, the relative abundance of the high mobility species 
marked with a pink dot varies significantly among the four FDB muscle groups, ranging from ~21% 
in young wild type to 5% in young mdx tissue. In addition, the relative expression of the intermediate 
mobility species marked with a brown dot increases significantly in aged wild type (~10%) and mdx 
(~12%) FDB samples compared to young wild type tissue (~4%), but decreases dramatically (~1%) in 
young mdx tissue. On the contrary, the levels of the low (yellow dot) and intermediate (dark green 
and dark blue dots) mobility species remain relatively constant among the different FDB muscle groups 
Figure 9. Relative abundance and phosphorylation profile of sMyBP-C forms present in AH and 
gastrocnemius muscles from human patients carrying the DA-1 mutations. (a) The relative abundance 
of each immunoreactive band detected with the α -pan-sMyBP-C antibody following separation of protein 
lysates by phosphate affinity SDS-PAGE (Fig. 6b) was calculated as percent expression of the total protein 
content within each sample. Significance is as described in Fig. 6a’. (b) The phosphorylation events detected 
in each sMyBP-C form within the different samples were determined by comparative evaluation of the 
phosphate affinity SDS-PAGE immunoblots shown in Fig. 8. The colored dots correspond to sMyBP-C 
immunoreactive bands with specific electrophoretic mobility as determined by phosphate affinity SDS-PAGE, 
and thus may represent different (i.e. bands denoted with red, yellow, tan, and dark blue dots) or the same 
(bands denoted with light yellow, olive green, light green, turquoise, purple, and light purple dots) phospho-
species across the human samples.
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(34–41%, 20–33% and 4–5%, respectively). Lastly, the intermediate mobility species marked with tur-
quoise and purple dots exhibit low, yet similar, relative expression in all muscle groups (~3% and ~5%, 
respectively), with the following exceptions: i. the relative abundance of the former increases in young 
mdx FDB muscle (~9%), and ii. the latter is absent from aged wild type FDB muscle.
The phosphorylation profile of sMyBP-C in human abductor hallucis and gastrocnemius mus-
cles from DA-1 patients. Genome wide linkage analysis has revealed that mutations in MYBPC1 
encoding sMyBP-C lead to the development of Distal Arthrogryposis type-1 (DA-1)12. To date, DA-1 is 
the most common among the ~10 identified forms of distal arthrogryposis myopathy13. Two missense 
mutations in MYBPC1, W236R and Y856H residing in the M-motif and the C8 domain, respectively, 
have been linked to the development of DA-112. We have begun to assess the effect of each of these 
mutations on the phosphorylation profile of sMyBP-C. To this end, we used standard and phosphate 
affinity gel electrophoresis in combination with a panel of phospho-specific antibodies to examine the 
effects of the DA-1 mutations on the phosphorylation profile of sMyBP-C in distal and proximal muscles. 
Specifically, we used human biopsies of AH, a distal foot muscle carrying the Y856H mutation, and gas-
trocnemius, a proximal leg muscle containing the W236R mutation. Gastrocnemius muscle carrying the 
W236R mutation contains nearly identical levels of total and phosphorylated sMyBP-C protein compared 
to control tissue. However, AH muscle carrying the Y856H mutation exhibits significantly reduced levels 
of total sMyBP-C protein (~25%) and of phosphorylation at each of the four phospho-sites (~32–70%), 
compared to control tissue (Fig. 6). More importantly, the presence and relative abundance of individual 
phosphorylation events or combinations thereof vary considerably in AH muscle carrying the Y856H 
mutation, but not in gastrocnemius muscle containing the W236R mutation (Fig. 6a,b). These findings 
indicate that the phosphorylation profile of sMyBP-C is altered in pathologically affected distal muscles 
but not in unaffected proximal muscles in DA-1 myopathy.
Similar to soleus and FDB muscles, we again performed a comparative analysis of the results shown 
in Figs 6–8 to assess the relative abundance (Fig. 9a) and phosphorylation events present in individual 
sMyBP-C species (Fig. 9b) in control and DA-1 muscles. Of the six sMyBP-C forms expressed in control 
AH tissue, there are three highly abundant forms, one of low (red dot, ~27%) and two of intermediate 
(light yellow and dark blue dots; ~24% and 19%, respectively) mobility. Interestingly, no immunoreac-
tive band is phosphorylated at all four known sites in control AH muscle. With the exception of a low 
mobility species (blue dot) that is of low relative abundance (< 10%) and phosphorylated at all three sites 
present in the Pro/Ala rich motif, the remaining species are either singly or doubly phosphorylated at 
different combinations of residues.
Compared to control AH muscle, DA-1 AH muscle carrying the Y856H mutation exhibits a more 
complex phosphorylation profile (Fig.  9a). The most prominent species in DA-1 AH is a low mobility 
form (yellow dot), which exhibits a considerable increase (~30%), while three species, two of low (red and 
blue dots) and one of intermediate (light yellow dot) mobility exhibit lower relative abundance (~15%, 
~4%, and ~10%, respectively), compared to control tissue. Interestingly, three of the five species shared 
between control and DA-1 AH tissues (red, yellow, and blue dots) exhibit different phosphorylation 
profiles. Specifically, the low mobility species denoted by a red dot is doubly phosphorylated at hSer61 
and hSer206 in control AH tissue, but singly phosphorylated at hSer85 in DA-1 AH muscle. Similarly, 
the low mobility species marked with a blue dot is phosphorylated at all four known residues in DA-1 
AH, opposite to control AH where it is phosphorylated only at the three sites present within the Pro/Ala 
rich motif. These findings suggest that these species either correspond to sMyBP-C variants of different 
molecular weights and phosphorylation profiles that exhibit similar electrophoretic mobility, or to the 
same variant that is differentially phosphorylated between muscles, at known and/or unknown residues.
Similar analysis of control and DA-1 gastrocnemius muscle carrying the W236R mutation revealed 
no significant differences in the relative abundance or phosphorylation profile of individual sMyBP-C 
species.
Taken together, our findings show that the distal AH muscle carrying the Y856H mutation exhibits 
altered expression and phosphorylation of sMyBP-C, while the proximal gastrocnemius muscle carrying 
the W236R mutation does not. It is possible that these differential effects in distal and proximal mus-
cles may arise from the individual mutations. We find this highly unlikely though, given that previous 
studies have demonstrated that DA-1 AH muscles carrying either the W236R or the Y856H mutation 
exhibit similar pathologies, as evidenced by the presence of smaller type-I fibers compared to matching 
controls12. Thus, it is possible that the presence of the W236R mutation in AH muscle may also result in 
major alterations of the expression levels and the phosphorylation profile of sMyBP-C. Conversely, the 
presence of the Y856H mutation in gastrocnemius muscle may not have any effect in either its expression 
levels or its phosphorylation profile.
An important question that still remains, however, is how the Y856H mutation residing in Ig C8 at 
the COOH-terminus of the molecule affects its phosphorylation pattern within its NH2-terminus. It has 
been previously shown both in vitro and in vivo that the introduction of either DA-1 mutation does not 
alter the normal distribution of sMyBP-C to the sarcomeric A-band12,24,25. However, it is possible that 
the Y856H mutation may disrupt the proper orientation of sMyBP-C within the sarcomere, its confor-
mation or its tertiary structure, which in turn may result in reduced accessibility of its NH2-terminus to 
PKA and PKC. High-resolution cellular and structural studies may provide answers to this important 
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question and help us discern the underlying molecular mechanisms that lead to altered phosphorylation 
of sMyBP-C in DA-1 myopathy.
Concluding remarks. Using the fast-twitch mouse FDB muscle and the human AH and gastrocne-
mius muscles as model systems, we evaluated the phosphorylation profile of sMyBP-C in normalcy and 
under different pathophysiological conditions. Our studies are the first to demonstrate that the phos-
phorylation pattern of the sMyBP-C sub-family is differentially regulated in response to age and disease. 
Future studies will focus on the specific roles that each phosphorylation event or combinations thereof 
play on the functional properties of sMyBP-C proteins.
Methods
Animal Models and Tissue Collection. All animal protocols were conducted in accordance with the 
approved protocols of the Institutional Animal Care and Use Committee of the University of Maryland 
School of Medicine. FDB muscles were obtained from young (~2 months) and old (~14 months) 
adult male wild type C57BL/6Scsn/J and dystrophic mdx C57BL/10Scsn-Dmd mdx/J mice (Jackson 
Laboratories, Bar Harbor, ME). Immediately following isolation, tissues were snap-frozen in liquid nitro-
gen. Four (n = 4) FDB muscles were collected from different mice.
Human Tissue Samples. Human muscle biopsies of AH and gastrocnemius muscles carrying the 
DA-1 Y856H and W236R mutations, respectively, were obtained during reconstruction surgery; both 
patients exhibited similar levels of disease severity. Control AH and gastrocnemius muscles that do not 
contain the DA-1 mutations were obtained from 15- and 20-months old patients with clubfoot and a 
16-year old trauma patient with no myopathy, respectively. Tissue samples were flash-frozen in liquid 
nitrogen. Moreover, all tissue samples were collected in accordance with a protocol approved by the 
Institutional Review Board of the Washington University School of Medicine, and with the consent of 
all subjects. The available information for each human sample is noted in Table 1.
Generation of Protein Lysates and Western Blotting. Protein lysates from mouse FDB muscles 
were generated as previously described1. Lysates (~30 μ g) from each tissue were prepared for electro-
phoresis and heated at 90 °C for 5 minutes. Separation of proteins was conducted using either conven-
tional SDS-PAGE (Life Technologies, Carlsbad, CA)10,11, or phosphate affinity SDS-PAGE, according 
to the manufacturer’s instructions. Separation via phosphate affinity SDS-PAGE was performed using 
100 μ mol/L Phos-tagTM (Wako Chemicals USA, Inc. Richmond, VA), and a 10% w/v solution of acryla-
mide26. Following electrophoretic separation, lysates were subjected to western blot analysis and probed 
with the indicated antibodies. A pan-sMyBP-C antibody (mouse monoclonal; 300 ng/ml; Abnova, 
Walnut, CA) and an Hsp90 antibody (mouse monoclonal; 300 ng/ml; Cell Signaling Technology, Inc., 
Danvers MA) were used per the manufacturers’ instructions. Evaluation of the entire lanes following 
immunoprobing with the pan-sMyBP-C antibody indicated the absence of any (detectable) degradation 
of sMyBP-C in the mouse and human muscle lysates (SFig. 1). In addition, phospho-specific custom pol-
yclonal antibodies to each of the phospho-sites of sMyBP-C, mSer-59/hSer-61, mSer-62/hThr-64, mThr-
84/hSer-85, and mSer-204/hSer-206 were used (750 ng/ml, Ackermann et al. 2014; Companion paper). 
Antibody validation and specificity are described in detail in (Ackermann et al. 2014; Companion paper).
Statistical Analysis. Using standard SDS-PAGE blots and ImageJ software (NIH, Bethesda, MD), 
we quantified the relative content of total sMyBP-C and the relative expression of each phosphorylated 
residue within a sample. Percent (%) expression was normalized to the loading control, Hsp90, and 
subsequently to the levels of sMyBP-C present in the mouse young wild type FDB or the appropriate 
human control clubfoot muscle. Significance was calculated via student’s t-test (p < 0.01). Moreover, we 
quantified the relative abundance of individual immuno-reactive bands within a sample using Image 
J software. To this end, the quantified relative content of total sMyBP-C for each sample calculated 
above, served as a representation of total sMyBP-C protein within that sample. The relative abundance 




5432001 W236R M 5 yr Gastrocnemius Distal arthrogryposis-1
8039001 Y856H M 3 yr Abductor Hallucis Distal arthrogryposis-1
2017 None M 16 yr Gastrocnemius Trauma/No myopathy
5263004 Unknown M 15 mos Abductor Hallucis Bilateral clubfoot, familial
5476001 Unknown M 20 mos Abductor Hallucis Left clubfoot, familial
Table 1.  Control and DA-1 mutant human tissue samples.
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antibody was calculated as a percentage of the total protein within that sample. Furthermore, we used 
the phosphate affinity SDS-PAGE western blots probed with each of the phospho-specific antibodies 
to ascertain the phosphorylation events within a specific immuno-reactive band detected with the 
pan-sMyBP-C antibody.
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